PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2017.31520185031009-1022Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor GrowthJaehyun Lee, Yong Jae Shin, Kyoungmin Lee, Hee Jin Cho, Jason K. Sa, Sang-Yun Lee, Seok-Hyung Kim, Jeongwu Lee, Yeup Yoon, Do-Hyun Namhttp://e-crt.org/upload/pdf/crt-2017-315.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2017.315, http://www.e-crt.org/upload/pdf/crt-2017-315.pdf
Neuro-Oncology10.1093/neuonc/noac209.871202224Supplement_7vii226-vii226EXTH-73. A NOVEL ANTI-GALECTIN-3 MONOCLONAL ANTIBODY THERAPEUTIC DIMINISHES MIGRATION AND SLOWS TUMOR GROWTH TO PROLONG SURVIVAL IN GLIOBLASTOMAAnne Marie Barrette, Krutika Deshpande, Marvin Cadiente, Xi Wang, Dongxu Sunhttps://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii226/47020552/noac209.871.pdf, https://academic.oup.com/neuro-oncology/article-pdf/24/Supplement_7/vii226/47020552/noac209.871.pdf
IUBMB Life10.1002/iub.10642012649757-765A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growthYuhe Qiu, Zhixin Zhang, Juan Shi, Shilian Liu, Yanxin Liu, Dexian Zhenghttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fiub.1064, http://onlinelibrary.wiley.com/wol1/doi/10.1002/iub.1064/fullpdf
Neuro-Oncology10.1093/neuonc/noab196.706202123Supplement_6vi178-vi178EXTH-67. THERAPEUTIC EFFICACY OF GC1118, A NOVEL ANTI-EGFR ANTIBODY, AGAINST GLIOBLASTOMA WITH HIGH EGFR AMPLIFICATION IN PATIENT-DERIVED XENOGRAFTSSeung Won Choihttps://academic.oup.com/neuro-oncology/article-pdf/23/Supplement_6/vi178/41140308/noab196.706.pdf, https://academic.oup.com/neuro-oncology/article-pdf/23/Supplement_6/vi178/41140308/noab196.706.pdf
Molecular Therapy10.1016/s1525-0016(16)36597-2201119S1025. Genetically Modified T Cells Directed to Glioblastoma Suppress Tumor Growth in a Rodent Glioma Modelhttps://api.elsevier.com/content/article/PII:S1525001616365972?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525001616365972?httpAccept=text/plain
Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies10.1016/b978-0-12-821584-5.00031-6202375-81Targeting ERBB2 overcomes resistance to the anti-EGFR therapeutic antibody cetuximabChuqi Wang, Tian Li, Wenyan Fu, Shi Huhttps://api.elsevier.com/content/article/PII:B9780128215845000316?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:B9780128215845000316?httpAccept=text/plain
Ophthalmology10.1016/s0161-6420(80)35105-1198087121236-1238Interferon as an Antiviral and Anti-tumor Therapeutic AgentAnn M. Arvinhttps://api.elsevier.com/content/article/PII:S0161642080351051?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0161642080351051?httpAccept=text/plain
Molecular Therapy10.1016/s1525-0016(16)37105-2201119S204532. Neuropilin-1 Expressing Mononuclear Cells (NEMs), a Novel Population of Bone Marrow Cells Recruited by AAV2-Sema3A, Contributes to Vessel Normalization and Inhibits Tumor Growthhttps://api.elsevier.com/content/article/PII:S1525001616371052?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525001616371052?httpAccept=text/plain
Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies10.1016/b978-0-12-821584-5.00004-3202383-89CT16: A dual antibody targeting both EGFR and Notch suppresses EGFR blockage and radiation resistance by decreasing tumor-initiating cell frequencyKewen Qian, Changhai Lei, Shi Huhttps://api.elsevier.com/content/article/PII:B9780128215845000043?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:B9780128215845000043?httpAccept=text/plain
Neuro-Oncology10.1093/neuonc/noaa215.373202022Supplement_2ii90-ii91EXTH-19. EVALUATING THE ANTI-TUMOR EFFECT OF A NOVEL THERAPEUTIC AGENT, MAGMAS INHIBITOR, IN MALIGNANT GLIOMAKaijun Di, Senjie Du, Javier Lepe, Nitesh Nandwana, Bhaskar Das, Daniela Botahttp://academic.oup.com/neuro-oncology/article-pdf/22/Supplement_2/ii90/34689728/noaa215.373.pdf, http://academic.oup.com/neuro-oncology/article-pdf/22/Supplement_2/ii90/34689728/noaa215.373.pdf